Compare · ANL vs NVO
ANL vs NVO
Side-by-side comparison of Adlai Nortye Ltd. (ANL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 223.1x ANL ($778.6M).
- ANL has been more active in the news (7 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 8 for ANL).
- Company
- Adlai Nortye Ltd.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $778.6M
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 7
- 4
- Recent ratings
- 8
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANL
- SEC Form 6-K filed by Adlai Nortye Ltd.
- Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
- Director Ji Ping sold $163,275 worth of American Depository shares (10,214 units at $15.99), decreasing direct ownership by 8% to 121,453 units (SEC Form 4)
- SEC Form 6-K filed by Adlai Nortye Ltd.
- Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
- SEC Form 6-K filed by Adlai Nortye Ltd.
- Director Ji Ping sold $83,150 worth of American Depository shares (5,000 units at $16.63), decreasing direct ownership by 4% to 131,667 units (SEC Form 4)
- SEC Form EFFECT filed by Adlai Nortye Ltd.
- SEC Form S-8 POS filed by Adlai Nortye Ltd.
- SEC Form S-8 POS filed by Adlai Nortye Ltd.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank